AU2013215468A1 - Benzyl sulfonamide derivatives useful as MOGAT - 2 inhibitors - Google Patents

Benzyl sulfonamide derivatives useful as MOGAT - 2 inhibitors Download PDF

Info

Publication number
AU2013215468A1
AU2013215468A1 AU2013215468A AU2013215468A AU2013215468A1 AU 2013215468 A1 AU2013215468 A1 AU 2013215468A1 AU 2013215468 A AU2013215468 A AU 2013215468A AU 2013215468 A AU2013215468 A AU 2013215468A AU 2013215468 A1 AU2013215468 A1 AU 2013215468A1
Authority
AU
Australia
Prior art keywords
compound according
ethyl
compound
methyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013215468A
Other languages
English (en)
Inventor
Maria Carmen Fernandez
Maria Rosario Gonzalez-Garcia
Lance Allen Pfeifer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013215468(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013215468A1 publication Critical patent/AU2013215468A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2013215468A 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as MOGAT - 2 inhibitors Abandoned AU2013215468A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
US61/592,717 2012-01-31
EP12382432.8 2012-11-06
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Publications (1)

Publication Number Publication Date
AU2013215468A1 true AU2013215468A1 (en) 2014-07-10

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013215468A Abandoned AU2013215468A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as MOGAT - 2 inhibitors

Country Status (27)

Country Link
US (1) US8575352B2 (https=)
EP (1) EP2809651B1 (https=)
JP (1) JP2015511232A (https=)
KR (1) KR20140106750A (https=)
CN (1) CN104066719B (https=)
AP (1) AP2014007794A0 (https=)
AR (1) AR089771A1 (https=)
AU (1) AU2013215468A1 (https=)
BR (1) BR112014018636A8 (https=)
CA (1) CA2859995A1 (https=)
CL (1) CL2014001861A1 (https=)
CO (1) CO7010839A2 (https=)
CR (1) CR20140322A (https=)
DO (1) DOP2014000178A (https=)
EA (1) EA201491276A1 (https=)
ES (1) ES2590929T3 (https=)
GT (1) GT201400167A (https=)
HK (1) HK1199025A1 (https=)
IL (1) IL233712A0 (https=)
MA (1) MA35886B1 (https=)
MX (1) MX2014008599A (https=)
PE (1) PE20141679A1 (https=)
PH (1) PH12014501711A1 (https=)
SG (1) SG11201404106QA (https=)
TW (1) TW201343629A (https=)
WO (1) WO2013116075A1 (https=)
ZA (1) ZA201404836B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
BR112014018712A8 (pt) 2012-01-31 2017-07-11 Lilly Co Eli Derivados de morfolinila úteis como inibidores de mogat-2
US9416138B2 (en) 2012-11-06 2016-08-16 Eli Lilly And Company Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
MX389242B (es) 2015-06-15 2025-03-20 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
MX2021008050A (es) 2019-01-11 2021-08-05 Shionogi & Co Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
AU2005303492A1 (en) * 2004-11-10 2006-05-18 Pfizer Inc. Substituted N-sulfonylaminobenzyl-2-phenoxy acetamide compounds
CN101511808A (zh) * 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
EP2078719A4 (en) 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
CN101583593A (zh) * 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2010216633A1 (en) 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
BR112014018712A8 (pt) 2012-01-31 2017-07-11 Lilly Co Eli Derivados de morfolinila úteis como inibidores de mogat-2

Also Published As

Publication number Publication date
PE20141679A1 (es) 2014-11-08
US8575352B2 (en) 2013-11-05
SG11201404106QA (en) 2014-08-28
CN104066719B (zh) 2016-08-24
JP2015511232A (ja) 2015-04-16
KR20140106750A (ko) 2014-09-03
IL233712A0 (en) 2014-09-30
CN104066719A (zh) 2014-09-24
AP2014007794A0 (en) 2014-07-31
DOP2014000178A (es) 2014-08-31
CL2014001861A1 (es) 2014-11-07
TW201343629A (zh) 2013-11-01
EA201491276A1 (ru) 2014-10-30
HK1199025A1 (en) 2015-06-19
CA2859995A1 (en) 2013-08-08
US20130197039A1 (en) 2013-08-01
WO2013116075A1 (en) 2013-08-08
CO7010839A2 (es) 2014-07-31
MX2014008599A (es) 2014-08-22
MA35886B1 (fr) 2014-12-01
ZA201404836B (en) 2017-08-30
EP2809651A1 (en) 2014-12-10
PH12014501711A1 (en) 2014-10-13
EP2809651B1 (en) 2016-06-29
ES2590929T3 (es) 2016-11-24
AR089771A1 (es) 2014-09-17
GT201400167A (es) 2015-05-28
CR20140322A (es) 2014-08-25
BR112014018636A2 (https=) 2017-06-20
BR112014018636A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
EP2809651B1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
JP5826972B2 (ja) 酸セラミダーゼインヒビターおよびそれらの医薬としての使用
US9073856B2 (en) Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
HK1224172A1 (zh) 用於诱导软骨形成的化合物和方法
AU2013215549B2 (en) Novel morpholinyl derivatives useful as MOGAT-2 inhibitors
CN113924288B (zh) 一种含喹啉基化合物、药物组合物以及其用途
WO2018085263A1 (en) Compounds for treatment of neurodegenerative diseases
CN107129465B (zh) 芳基胍类化合物及其制备方法和用途
CN105777718A (zh) 潜在ezh2小分子抑制剂及其合成方法
RU2803116C2 (ru) Хинолинил-содержащее соединение и его фармацевтическая композиция и применение
WO2019120198A1 (zh) 一类喹啉衍生物
WO2026086905A1 (zh) 一种作为钠通道调节剂的化合物的前药及其用途
CN103012274B (zh) 异羟肟酸类化合物，制备方法和用途
BR122025005591A2 (pt) Uso de e processo para preparação de derivados de ciclobutila 1,3-substituída, combinação farmacêutica, e kit
HK1199024B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
EA045074B1 (ru) Соединения пирролидина
HK1241267A1 (en) Compounds and methods for inducing chondrogenesis
CN110452253A (zh) Mcl-1选择性抑制剂及其制备和用途
BRPI0910391A2 (pt) Compostos moduladores do receptor prostaciclina (pgi2), forma cristalina dos referidos compostos, composição farmacêutica, usos dos mesmos e processo para preparação da referida composição

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period